Sphere Medical : Notice of Interim Results

Sphere Medical Holding plc



For immediate release                                                                             26 August 2014

Sphere Medical Holding plc

("Sphere Medical" or the "Company")

Notice of Interim Results

Cambridge, UK, 26 August 2014: Sphere Medical Holding plc (AIM: SPHR.L), a leading developer of innovative monitoring and diagnostic products for the critical care setting, will announce its interim results for the six months ended 30 June 2014 on Monday 15 September 2014.

Dr Wolfgang Rencken, Chief Executive Officer, and Matthew Hall, Chief Financial Officer, will host a presentation for analysts at 10.30am on the morning of the results at Consilium Strategic Communications' offices, 41 Lothbury, London, EC2R 7HG.

- Ends -

For further information, please contact:

Sphere Medical Holding plc	Tel: [phone]
Dr Wolfgang Rencken, Chief Executive Officer
Matthew Hall, Chief Financial Officer
Peel Hunt LLP	Tel: [phone]
James Steel
Clare Terlouw
Jock Maxwell Macdonald
finnCap	Tel: [phone]
Geoff Nash / Simon Hicks
Stephen Norcross
Consilium Strategic Communications	Tel: [phone]
Mary-Jane Elliott	[e-mail]
Amber Bielecka
Matthew Neal
Ivar Milligan

Notes for Editors

Sphere Medical (AIM: SPHR.L), is a medical device company developing a range of innovative monitoring and diagnostic devices designed to significantly improve patient care.

Sphere Medical's products deliver real time analysis of blood gases, electrolytes and drug levels with laboratory accuracy, at the patient's bedside.  Sphere Medical's products can be used in a wide range of medical applications, enabling faster clinical decision making and improved patient outcomes, whilst reducing costs for healthcare payers.

Sphere Medical entered into a collaboration agreement with Ortho-Clinical Diagnostics, Inc. for the development of Proxima and enhancement of Sphere's operational and production capabilities in 2013.

Sphere Medical has a number of partnerships with industry leading medical device companies and has received a strategic investment from Ortho Clinical Diagnostics (now part of Carlyle Group).  Other significant investors include Life Sciences Partners (LSP Life Sciences Fund).

This information is provided by RNS

The company news service from the London Stock Exchange

ENDNORLIFERTVIRFIS